The frequency of follow up tests for Multiple Sclerosis (MS) is not the same for everyone; it depends on the stability of the condition, the type of treatment being used, and any changes in symptoms. Generally, the goal of regular testing is to detect new disease activity before it leads to physical relapses and to ensure that medications are being used safely. In the United Kingdom, the National Institute for Health and Care Excellence (NICE) provides a framework that ensures every person with MS has at least one comprehensive clinical review per year. However, for those on specific disease-modifying therapies (DMTs) or those recently diagnosed, testing occurs much more frequently to monitor for side effects and early treatment response.
Multiple Sclerosis is a dynamic condition where the immune system can cause inflammation in the brain or spinal cord even when a person feels perfectly well. This is why regular monitoring is essential. By using a combination of neurological exams, Magnetic Resonance Imaging (MRI), and blood tests, your clinical team can build a clear picture of your health. This proactive approach allows for timely adjustments to treatment plans, which is a key factor in protecting long-term neurological function. This article outlines the typical schedules for various MS tests and the factors that might require more frequent check ups.
What We’ll Discuss In This Article
- The standard for annual comprehensive clinical reviews
- Recommended frequency for follow up MRI scans
- Blood monitoring schedules for different disease modifying therapies
- Monitoring requirements for safety and side effect management
- Factors that might trigger more frequent testing
- Emergency guidance for sudden neurological changes
Annual Comprehensive Clinical Reviews
In line with national health standards, everyone living with Multiple Sclerosis should be offered a comprehensive review of all aspects of their care at least once a year. This review is typically carried out by a healthcare professional with expertise in MS, such as a neurologist or a specialist MS nurse.
The purpose of this annual check is to assess your mobility, balance, cognitive function, and any new or worsening symptoms like fatigue or pain. It is also an opportunity to review your current medication and discuss your general well being. For many, this annual meeting serves as the baseline for their care. If you are on a disease-modifying therapy, this annual review is a mandatory requirement to ensure the treatment is still appropriate and effective for you.
MRI Monitoring Frequency
MRI scans are the most sensitive way to detect new inflammation or lesions in the central nervous system. While there is no single rule for how often an MRI should be performed, several clinical milestones usually trigger a scan.
Post Diagnosis and Treatment Starts
When you are first diagnosed or when you start a new medication, a re baseline MRI is typically performed 6 months later. This scan is used as a new point of comparison to see how well the treatment is working.
Routine Monitoring
For individuals with Relapsing Remitting MS who are stable on treatment, an annual brain MRI is often recommended. This helps clinicians spot any silent lesions that do not cause obvious symptoms. If there has been no history of spinal cord involvement, spinal scans may be performed less frequently than brain scans.
Progressive MS
Blood Tests and Treatment Safety
If you are taking disease-modifying therapies, blood tests are a regular part of your routine. These tests are not usually looking at the MS itself but are instead monitoring how the medication is affecting your body, such as your liver function, kidney health, and white blood cell counts.
The frequency of these tests varies significantly depending on the specific drug:
- High Frequency Monitoring: Some treatments require monthly blood tests for the first few years to monitor for rare but serious autoimmune side effects.
- Moderate Frequency Monitoring: Other therapies may require tests every 3 to 6 months.
- Low Frequency Monitoring: Some oral or infusion treatments only require blood work twice a year or immediately before each treatment session.
Factors Influencing Test Frequency
Your clinical team may decide to increase the frequency of your tests based on specific life events or changes in your condition.
| Factor | Change in Monitoring | Reason for Change |
| New Relapse | Urgent MRI and clinical review. | To confirm new activity and assess recovery. |
| Switching DMTs | Re baseline MRI at 3 to 6 months. | To establish a new starting point for the drug. |
| PML Risk (JCV Positive) | MRI every 3 to 6 months. | Safety monitoring for high risk treatment complications. |
| Pregnancy | Post partum MRI at 3 to 6 months. | Disease activity often fluctuates after giving birth. |
| Cognitive Changes | Neuropsychological testing. | To assess memory and processing speed changes. |
Emergency Guidance
While routine follow up tests are scheduled in advance, some situations require immediate medical attention. If you experience any of the following, do not wait for your next scheduled appointment:
- Sudden and total loss of vision in one eye.
- Severe weakness in your limbs that makes it impossible to walk or stand.
- Significant new difficulty with breathing or swallowing.
- A sudden, severe change in your level of consciousness or confusion.
In these instances, seek emergency medical care immediately by calling 999.
To Summarise
The frequency of follow-up tests for Multiple Sclerosis is tailored to your individual needs and treatment plan. At a minimum, you should expect an annual clinical review to assess your overall health and medication. MRI scans are typically performed annually for those on active treatment, with a re baseline scan 6 months after starting a new therapy. Blood tests vary from monthly to twice yearly, depending on the safety requirements of your specific medication. By staying consistent with these tests, you and your medical team can ensure that your treatment is working effectively and that any changes in your condition are managed promptly.
